Clinical Trial Update: High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 clinical trial evaluating high-dose pulsatile erlotinib or gefitinib in patients with advanced non-small cell lung cancer after f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Anhui Medical University | Conditions: Self Efficacy, Drug Toxicity | Phase 2 | Status: UNKNOWN